Our world has certainly changed in 2020. Not just our myeloma world, but the entire world has been affected by the SARS-CoV2 pandemic. There is good news for both challenges. There were 688 myeloma abstracts at ASH 2020 (179 orals / 500 posters / 9 publications). While this was less than in years past, it is still much […]
The 62nd American Society of Hematology annual meetings have ended but the experience is one that I will cherish for years to come. I was not sure what to expect from the virtual platform, but I was not disappointed in the end. The overall experience was more than I could have imagined. I enjoyed having […]
In December, 2012 I attended my first annual meeting of the American Society of Hematology (#ASH12) with the International Myeloma Foundation. The meeting was held at the Georgia World Congress Center in Atlanta. I had no idea on what to expect when I entered the convention center for the first time. I was walking around […]
After finishing two full days of watching abstracts and education sessions about multiple myeloma at the American Society of Hematology Conference (ASH), my head is spinning from the number of new combinations, therapies, and therapy targets. All of this is excellent news for us, but this makes treatment decisions much more complicated. This diagram presented by Dr. […]
“Bispecifics are the prom queens of ASH”—Tom Martin, M.D. Attending the virtual iteration of ASH has been a unique experience, in that I’ve had the opportunity to see many of the leading international myeloma experts all from the comfort of own home. One of the silver linings of a virtual symposium is that I have […]
Last year, in one of my ASH19 blogs, I wrote about bi-specific T cell engager (BiTE) therapy. BiTEs excite me the most of the newer therapies in clinical trials. They harness the power of the immune system and are off-the-shelf, unlike CAR T where your T cells are harvested, then re-engineered, then given back to you […]
The antibodies are front and center during the 2020 American Society of Hematology’s Annual Meeting. I thought this would be a good time to review the mechanism of action (how they work) of each type of antibody. The first antibodies to make it to the myeloma scene were the monoclonal antibodies. (mAbs) Monoclonal antibodies in […]
